Pharma: Other News To Note
Monday, February 25, 2013
Lupin Ltd., of Mumbai, India, said its subsidiary, Lupin Pharmaceuticals Inc., received approval for Suprax (cefixime) for oral suspension, 500 mg/5mL from the FDA. The approval will expand Lupin's range of Suprax dosage forms available to treat approved indications in appropriate patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.